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Abstract 
Hypertension (HT) is considered the main
classic vascular risk factor for stroke and the
importance of lowering blood pressure (BP) is
well established. However, not all the benefit of
antihypertensive treatment is due to BP reduc-
tion per se, as the effect of reducing the risk of
stroke differs among classes of antihyperten-
sive agents. Extensive evidences support that
angiotensin-converting  enzyme  inhibitors
(ACEI),  angiotensin  II  receptor  blockers
(ARB), dihydropyridine calcium channel block-
ers (CCB) and thiazide diuretics each reduced
risk  of  stroke  compared  with  placebo  or  no
treatment. Therefore, when combination ther-
apy is required, a combination of these antihy-
pertensive  classes  represents  a  logical
approach. Despite the efficacy of antihyperten-
sive therapy a large proportion of the popula-
tion,  still  has  undiagnosed  or  inadequately
treated HT, and remain at high risk of stroke.
In  primary  stroke  prevention  current  guide-
lines recommend a systolic/diastolic BP goal of
<140/<90 mmHg in the general population and
<130/80  mmHg  in  diabetics  and  in  subjects
with  high  cardiovascular  risk  and  renal  dis-
ease. The recent release in the market of the
fixed-dose combination (FDC) of ACEI or ARB
and CCB should provide a better control of BP.
However to confirm the efficacy of the FDC in
primary  stroke  prevention,  clinical  interven-
tion trials are needed.   
Introduction
Stroke is a leading cause of death and dis-
ability  worldwide,  exacting  an  enormous
financial toll.1 The total incidence of stroke is
expected  to  increase  considerably  over  the
next  two  decades  particularly  in  European
Union where the estimated number of stroke
events  will  increase  to  1,500,000  by  2025.2
Among the risk factors for stroke, epidemiolog-
ical  studies  carried  out  in  the  past  decades
have definitely established that arterial hyper-
tension  (HT)  is  the  main  risk  factor  for
stroke,3,4 and that its disabling complications
are directly associated to the severity of blood
pressure (BP) increase.5
However,  other  evidences  have  been  out-
lined that the risk of stroke associated with
high BP values is not irreversible, as the risk of
stroke incidence could be strongly reduced if
BP values were controlled by and optimal anti-
hypertensive treatment.6 The latter is funda-
mental for stroke prevention as the early dis-
continuation  of  the  anti-hypertensive  treat-
ment is associated with a 30% increase in risk
of stroke.7 In this respect all anti-hypertensive
drugs  classes  may  be  useful  in  preventing
stroke, but some of these may exert a cere-
brovascular protection independently to their
BP reduction.6
This paper reviews the role of HT as a risk
factor for stroke, provides an update on which
is the antihypertensive treatment recommend-
ed in primary stroke prevention and explores
the potential efficacy of fixed-dose combina-
tion therapy in preventing stroke.            
Hypertension and risk of stroke
Approximately 54% of strokes can be attrib-
uted worldwide to high BP values in both gen-
der and in all ages.4 As a consequence, hyper-
tensive subjects are 3 to 4 times more likely to
have a stroke than the normotensives.8 In par-
ticular, it was established that a 2 mmHg rise
in systolic BP in middle life is associated with
10% increase in risk of stroke.9 In addition the
relationship between BP and risk of first stroke
is  direct,  continuous  and  independent,  with
the risk increasing continuously above a BP of
115/75 mmHg.5
Among BP components, many researchers
have established a different role of systolic and
diastolic  on  cerebrovascular  risk,  especially
when diastolic is associated with high systolic
levels.  This  association  determines  an
increase  of  the  pulsatile  component  of  BP
(pulse pressure, PP). The increase of PP is an
age-related phenomenon10 and it is commonly
believed that PP is an indicator of large artery
stiffness.11 High PP is associated with higher
incidence of carotid stenosis12,13 and reduction
in cerebral flow,14,15 and is recognized as an
independent predictors of stroke mortality16,17
particularly in elderly people from general pop-
ulation.18 In particular, 10 mmHg PP increases
is  associated  with  11%  increase  in  stroke.19
Increase in systolic and decrease in diastolic
BP results in high prevalence of isolated sys-
tolic  hypertension  (ISH),  defined  as  systolic
≥140  with  diastolic  <90  mmHg.  ISH  is  the
most common form of HT in the elderly, and a
major risk factor for stroke and cardiovascular
disease.20 Large-scale placebo-controlled clini-
cal  trials  have  demonstrated  the  efficacy  on
stroke  prevention  of  treating  elderly  with
ISH.21,22 However the studies of Langer et al.23
and of Benetos et al.24 showed higher stroke
mortality  in  treated  hypertensives  having  a
prevalent decrease in diastolic. Low diastolic
levels  have  been  associated  with  increased
coronary events, a phenomenon known as the
J-curve effect.25 Interestingly, this relationship
was not observed for stroke and was not pres-
ent among patients who had undergone coro-
nary  revascularization.26 In  contrast  to  the
heart, the brain is very infrequently subjected
to J-curve effect as the brain’s blood flow auto-
regulation  depends  mostly  on  systolic  BP.27
This  was  confirmed  by  the  results  of  the
Ongoing Telmisartan Alone and in combina-
tion with Ramipril Global Endpoint Trial study
(ONTARGET),  where  no  J-curve  pattern  did
appear for stroke.28 For the latter the assump-
tion the lower the systolic BP, the lower the risk
was correct, and it was confirmed in a meta-
analysis  by  Staessen  et  al.29 who  found  in
treated and untreated elderly patients with ISH
low systolic levels be associated with a strong
benefit for stroke prevention.
Blood pressure targets to achieve
in primary stroke prevention
Despite the overwhelming evidence that HT
represents the first risk factor for stroke and
that  the  cerebrovascular  benefits  the  most
from BP lowering, no randomized clinical trials
provided a BP target for effective primary pre-
vention  of  stroke.30 Current  international
guidelines recommend a systolic/diastolic goal
of <140/<90 mmHg in the general population
and <130/<80 mmHg in diabetic subjects and
in  those  with  renal  disease.31,32 Whether  a
lower target has further benefits in primary
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meta-analysis  comparing  trials  with  more-
intensive than those with less-intensive tar-
gets of BP found a 23% reduced risk of stroke
in  the  former  than  in  the  latter,  the  target
<140/<90  mmHg  was  not  achieved.33 In  the
HOT study there was no difference in rates of
stroke among groups of hypertensive patients
who achieved mean diastolic values of 85.2,
83.2 or 81.1 mmHg.34 For ISH, no trial has been
performed.  Finally,  the  investigators  of  the
HYVET trial35 provided evidence that antihy-
pertensive treatment is beneficial also in the
elderly and in very-elderly subjects (>80 years
of age); the latter a group excluded from most
other trials of antihypertensive therapy. The
primary end point of HYVET was fatal or nonfa-
tal  stroke.  At  two  years  of  follow-up,  active
treatment was associated with a 30% reduction
in the rate of all strokes and a 39% reduction in
the rate of death from fatal stroke. The greater
reduction of risk was observed for a BP target
of  <150/<80  mmHg  in  treated  patients  over
age 80, but the efficacy of further reductions in
BP needs to be established.
What are the available evidences
with renin angiotensin system
blockade? 
In the hypertensives, the renin angiotensin
system (RAS) has been linked to the risk of
stroke.36,37 Therefore,  it  has  been  suggested
that RAS blockade would provide a neuropro-
tective  effect.  In  the  literature  studies  with
ACEI  have  produced  different  results  in  pri-
mary stroke prevention. In the Heart Outcomes
Prevention Evaluation (HOPE) study, ramipril
reduced all stroke by 32% and fatal stroke by
61% compared with placebo.38 On the contrary,
in the Captopril Prevention Project, fatal and
nonfatal strokes were found to be more fre-
quent in patients randomized to captopril than
to  conventional  therapy.39 In  the  ALLHAT,
lisinopril  was  less  effective  in  preventing
stroke  than  diuretic  therapy.40 As  a  conse-
quence, the common belief in that in clinical
practice ACEI in primary stroke prevention it
has  yet  to  be  fully  confirmed.  On  the  other
hand,  it  has  been  well  established  that  the
inhibition  of  the  negative  effects  of
angiotensin in the cerebral circulation by ARB,
determines  a  neuroprotective  effect  through
the over activation of the AT2 receptors (see
below).  This  observation  comes  from  large
clinical trials. In the LIFE study, that enrolled
hypertensive  patients  with  left  ventricular
hypertrophy, losartan significantly reduced the
rate of fatal and nonfatal stroke by 25%.41 In
the  SCOPE,  candesartan-based  treatment
reduced non-fatal stroke by 30% and all stroke
by 24% compared with placebo in elderly sub-
jects.42 In  the  JIKEI  Heart  study,  the  HTs
receiving valsartan had a significant reduction
of stroke risk when compared with those not
taking ARB.43 Valsartan and other ARB appear
to reduce the risk of stroke more than placebo
in primary stroke prevention. This result was
also  confirmed  in  a  meta-analysis  of  about
50,000  patients,  where  treatment  with  ARB
were associated with a significant reduction of
stroke risk (∼8%) compared with ACEI.44
In conclusion the cerebrovascular benefits
of ARB seem to be class-related rather than
drug-related and in general all ARB might be
used in primary stroke prevention.
Are there evidences with CCB?
Different studies have compared the effects of
CCB vs. placebo or an active treatment for pre-
venting  stroke  events.45-47 In  particular,
nitrendipine-based treatment reduced the inci-
dence of fatal and nonfatal stroke by 38%.48In the
ACTION study, nifedipine GITS reduced the risk
of any stroke or TIA by 30% compared with place-
bo in hypertensive patients whit high cardiovas-
cular risk.49 CCB have also been shown to pro-
vide better protection against fatal and nonfatal
stroke  than  older  drugs,  such  as  ʲ-blockers,
diuretics  and  ACEI.50,51 This  has  particularly
been observed in a meta-analysis involving 4 tri-
als, where CCB have been shown to provide ben-
efit  compared  to  ACEI.52 In  the  ASCOT  study,
amlodipine reduced fatal and nonfatal stroke bet-
ter than atenolol (+23%).53,54 Moreover, the risk
of stroke with amlodipine was statistically less
when compared with non-ARB antihypertensive
drugs and with ARB therapies separately. 
What are the available evidences
with diuretics?
In the literature, it is well known that diuret-
ic  therapy,  particularly  thiazide  diuretics,
reduced the risk of stroke compared to placebo
or to no antihypertensive treatment.55 This has
particularly been observed in the elderly with
ISH. In the Systolic Hypertension in the Elderly
Program (SHEP) chlorthalidone caused a 36%
reduction  in  the  incidence  of  stroke.56 The
SHEP documented that the benefit of BP lower-
ing therapy is maintained also in very elderly
hypertensives aged ≥80 years.57 Another meta-
analysis found that diuretic therapy was superi-
or  to  ACEI  therapy,58 particularly  in  blacks.40
However, because of their lower tolerance and
efficacy on regression of target organ damage
compared with ARB, ACEI and CCB, in clinical
practice diuretics are rarely used alone as first-
line treatment for primary stroke prevention.
What is the mechanism of modula-
tion of the pathophysiology of
stroke by renin angiotensin system
blockade and CCB?   
Lowering BP is per se the most important
determinant  of  stroke  risk  reduction.59 This
has  particularly  been  observed  with  CCB.35
However this benefit appears in part independ-
ent of BP lowering.54,60 The same result were
been found with ARB, suggesting that these
agents also have some BP-independent bene-
fits. In experimental animal models, pre-treat-
ment with an ARB at a sub-antihypertensive
dose  was  more  effective  than  an  ACEI  for
reducing infarct size and neurological deficits
following transient focal ischemia.61
The  mechanisms  by  which  CCB  and  ARB
prevent  stroke  beyond  BP  reductions  is
unknown, although it is common belief that
these  antihypertensive  drugs  promote  their
protective action on stroke by reducing the pro-
gression  towards  the  vascular  and  cardiac
organ damage associated with hypertension.62
The increase of carotid intima-media thick-
ness (IMT) is an independent risk factor of
stroke63 and it is well established that - despite
comparable reductions in BP - CCB reduce IMT
more  than  ACEI  do.64 This  has  particularly
been  observed  in  the  INSIGHT  study,  where
the  hypertensives  receiving  nifedipine  gas-
trointestinal-transport-system  (GITS)  had
greater regression of IMT than those taking
diuretic.65
In the same manner, ARB reduce IMT more
than atenolol despite a similar effect on BP, an
effect that seems to be mediated by improve-
ments in nitric oxide production and decreas-
es in oxidative stress.66,67 Changes in central
aortic pressure but not in peripheral BP could
explain  some  differences  between  CCB  and
other  antihypertensive  drugs.  In  the  CAFE
study, despite comparable brachial pressures,
amlodipine-based  treatment  reduced  central
systolic BP more than atenolol.68 It has been
suggested that heart rate is a major determi-
nant  of  the  difference  between  central  and
brachial  BP,  and  might  account  for  the  less
effective lowering of central BP with atenolol.
As a consequence, in the CAFE study the effect
on  central  BP  and  heart  rate  could  explain
some  of  the  differences  in  stroke  incidence
between atenolol and amlodipine. 
The increase of left ventricular mass is an
independent risk factor for stroke.6 In a meta-
analysis, CCB and ARB were reported to reduce
left ventricular mass index by 11% and 13%,
respectively.69
There  is  evidence  that  antihypertensive
treatment with ARB and ACEI prevents new-
onset of non-valvular atrial fibrillation, a con-
dition  that  is  common  in  the  hypertensives
and  associated  with  5-fold  increased  risk  of
embolic  stroke.70 RAS  blockade  appears  to
reduce  the  incidence  of  stroke  by  51%  in
patients  with  new-onset  atrial  fibrillation.71
Although results obtained from the few clinical
studies were mostly post-hoc analysis, the ben-
efits in terms of stroke prevention seem to be
superior in subjects with cardiac damage sec-
ondary to HT and with heart failure.71-75
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Despite the availability of a wide range of
antihypertensive agents, almost two-thirds of
the hypertensives fail to achieve the BP goals
recommended  by  current  ESH/ESC  hyperten-
sion guidelines and have poorly controlled BP.62
As a consequence, they remain at a high risk of
morbid and fatal stroke and require effective
treatment options. Sub-optimal BP control is
often  due  to  poor  patient  compliance  and
results in a significant health and economic
burden. Numerous clinical trials have shown
that most patients require at least two antihy-
pertensive agents to achieve adequate BP con-
trol  and  associated  significant  reductions  in
stroke  morbidity  and  mortality.  Combination
therapy using two drugs with different mecha-
nisms of action achieves better efficacy and tol-
erability outcomes than treatment with either
component drug alone. Furthermore, when this
combination  is  administered  as  a  fixed-dose
combination, other benefits are achieved, such
as  an  improved  compliance  and  potentially
lower costs of treatment. The good efficacy and
tolerability of the fixed-dose of a CCB with an
ACEI or an ARB is well established, and this
combination  is  recommended  in  the  reap-
praisal  of  the  ESH/ESC  guidelines  as  a  first
choice in high-risk hypertensive patients.31 In
clinical  trials  the  fixed-dose  combination
improves BP to a greater extent than either
drug as monotherapy and, when compared with
antihypertensive mono-therapies, it may also
offer equivalent or better efficacy and the same
or improved tolerability. Therefore, fixed-dose
combination has the potential to reduce both
the risk of stroke and the non‐drug healthcare
costs associated with HT. 
Direct neuroprotective benefit of
the antihypertensive agents
As mentioned above, RAS blockade seems to
determine a direct neuroprotective effect. This
is  particularly  true  for  ARB,  as  it  has  been
observed  that  angiotensin  II  induces  cere-
brovascular  hypertrophy  and  remodelling,
inhibits  endothelium-dependent  relaxation
and  disrupts  the  blood-brain  barrier.36 Two
types  of  angiotensin  II  receptors  have  been
implicated to explain this benefit.76,77 Type 1
receptors,  expressed  in  different  tissues,
induce  vasoconstriction,  sodium  and  water
retention,  smooth-muscle  proliferation,  and
vascular  endothelial  damage,  while  type  2
receptors, expressed in fetal tissues and up-
regulated in ischemic brain tissue, modulate
the type 1 receptor activity reducing inflamma-
tion  and  neuronal  apoptosis  and  inducing
vasodilation,  thereby  mediating  neuroprotec-
tive effect. 
There is some evidence that ARB may pro-
vide  greater  reduction  in  the  risk  of  stroke
than  diuretics,  long-acting  dihydropyridine
CCB,  ACEI  and  ʲ-blockers  despite  similar
reduction in BP.78 This evidence has particu-
larly  been  demonstrated  with  losartan  vs.
atenolol,41 candesartan  vs.  hydroclothiazide
[42] and eprosartan vs. nitrendipine79 in clin-
ical studies where the risk of stroke was low.
However, the ONTARGET study was unable to
show  a  significant  reduction  in  stroke  with
telmisartan than ramipril.28 In addition, CCB
and ARB seem to have BP-independent effects
on  stroke  in  animal  models,  probably  via  a
reduction of inflammation in cerebral micro-
vessels,80 protection  of  cerebral  circulation
(improving of cerebral blood flow auto-regula-
tion) and reduction of superoxide production
.81,82 However, these data should be cautiously
translated  to  humans,  where  these  mecha-
nisms have not been readily observed. 
Conclusions
Hypertension remains the most important
established  and  modifiable  classic  vascular
risk  factor  for  stroke,  and  antihypertensive
treatment the most effective strategy for pre-
venting stroke as well as other BP-related tar-
get organ damage. Reduction in BP is general-
ly more important than the choice of  specific
agents, but some classes of antihypertensives
offer direct neuroprotective benefit: those act-
ing on RAS blockade, CCB and thiazide diuret-
ics  represent  the  three  classes  with  the
strongest effect in primary stroke prevention.
The  use  of  fixed-dose  combination  of  these
drugs  may  increase  patient  compliance  and
persistence  to  antihypertensive  treatment.
However further studies are required to evalu-
ate the neuroprotective effect of FDC therapy
in primary stroke prevention.83
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